Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors.

× No keyword cloud information.

5 in total

1. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).

Authors: Cristina Oliveras-Ferraros; Bruna Corominas-Faja; Sílvia Cufí; Alejandro Vazquez-Martin; Begoña Martin-Castillo; Juan Manuel Iglesias; Eugeni López-Bonet; Ángel G Martin; Javier A Menendez
Journal: Cell Cycle Date: 2012-09-19 Impact factor: 4.534

2. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors: Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal: Cell Cycle Date: 2012-01-15 Impact factor: 4.534

3. Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.

Authors: Alexandre Vivot; Jacques Li; Jean-David Zeitoun; Samia Mourah; Perrine Crequit; Philippe Ravaud; Raphaël Porcher
Journal: Genet Med Date: 2015-12-17 Impact factor: 8.822

4. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.

Authors: Begoña Martin-Castillo; Eugeni Lopez-Bonet; Elisabet Cuyàs; Gemma Viñas; Sonia Pernas; Joan Dorca; Javier A Menendez
Journal: Oncotarget Date: 2015-10-20

5. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression.

Authors: Manuela Ferracin; Cristian Bassi; Massimo Pedriali; Sara Pagotto; Lucilla D'Abundo; Barbara Zagatti; Fabio Corrà; Gentian Musa; Elisa Callegari; Laura Lupini; Stefano Volpato; Patrizia Querzoli; Massimo Negrini
Journal: Mol Cancer Date: 2013-10-28 Impact factor: 27.401

5 in total